Top

Published in:

01-08-2010 | Original paper

Mumps and ovarian cancer: modern interpretation of an historic association

Authors: Daniel W. Cramer, Allison F. Vitonis, Simone P. Pinheiro, John R. McKolanis, Raina N. Fichorova, Kevin E. Brown, Todd F. Hatchette, Olivera J. Finn

Published in: Cancer Causes & Control | Issue 8/2010

Abstract

Background

Epidemiologic studies found childhood mumps might protect against ovarian cancer. To explain this association, we investigated whether mumps might engender immunity to ovarian cancer through antibodies against the cancer-associated antigen MUC1 abnormally expressed in the inflamed parotid gland.

Methods

Through various health agencies, we obtained sera from 161 cases with mumps parotitis. Sera were obtained from 194 healthy controls. We used an ELISA to measure anti-MUC1 antibodies and electro-chemiluminescence assays to measure MUC1 and CA 125. Log-transformed measurements were analyzed by t-tests, generalized linear models, and Pearson or Spearman correlations. We also conducted a meta-analysis of all published studies regarding mumps and ovarian cancer.

Results

Adjusting for assay batch, age, and sex, the level of anti-MUC1 antibodies was significantly higher in mumps cases compared to controls (p = 0.002). Free circulating levels of CA 125, but not MUC1, were also higher in cases (p = 0.02). From the meta-analysis, the pooled odds ratio estimate (and 95% CI) for the mumps and ovarian cancer association was 0.81 (0.68–0.96) (p = 0.01).

Conclusion

Mumps parotitis may lead to expression and immune recognition of a tumor-associated form of MUC1 and create effective immune surveillance of ovarian cancer cells that express this form of MUC1.

West RO (1966) Epidemiology study of malignancies of the ovaries. Cancer 19:1001–1007CrossRefPubMed

Wynder EL, Dodo H, Barber HR (1969) Epidemiology of cancer of the ovary. Cancer 23(2):352–370CrossRefPubMed

Newhouse ML, Pearson RM, Fullerton JM, Boesen EA, Shannon HS (1977) A case control study of carcinoma of the ovary. Br J Prev Soc Med 31(3):148–153PubMed

Menczer J, Modan M, Ranon L, Golan A (1979) Possible role of mumps virus in the etiology of ovarian cancer. Cancer 43(4):1375–1379CrossRefPubMed

Golan A, Joosting AC, Orchard ME (1979) Mumps virus and ovarian cancer. S Afr Med J 56(1):18–20PubMed

Cramer DW, Welch WR, Cassells S, Scully RE (1983) Mumps, menarche, menopause, and ovarian cancer. Am J Obstet Gynecol 147(1):1–6PubMed

Schiffman MH, Hartge P, Lesher LP, McGowan L (1985) Mumps and postmenopausal ovarian cancer. Am J Obstet Gynecol 152(1):116–118PubMed

Chen Y, Wu PC, Lang JH et al (1992) Risk factors for epithelial ovarian cancer in Beijing, China. Int J Epidemiol 21(1):23–29CrossRefPubMed

Merritt MA, Green AC, Nagle CM, Webb PM (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122(1):170–176CrossRefPubMed

10.

Cramer DW, Titus-Ernstoff L, McKolanis JR et al (2005) Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 14(5):1125–1131CrossRefPubMed

11.

Hamanaka Y, Suehiro Y, Fukui M et al (2003) Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 103(1):97–100CrossRefPubMed

12.

Alos L, Lujan B, Castillo M et al (2005) Expression of membrane-bound mucins (MUC1 and MUC4) and secreted mucins (MUC2, MUC5AC, MUC5B, MUC6 and MUC7) in mucoepidermoid carcinomas of salivary glands. Am J Surg Pathol 29(6):806–813CrossRefPubMed

13.

Fichorova RN, Richardson-Harman N, Alfano M et al (2008) Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem 80(12):4741–4751CrossRefPubMed

14.

Egger M, Smith G, Altman D (2001) Systematic reviews in health care: meta-analysis in context, 2nd edn. BMJ Publishing Group, London

15.

Baldus SE, Engelmann K, Hanisch FG (2004) MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 41(2):189–231CrossRefPubMed

16.

Vlad AM, Finn OJ (2004) Glycoprotein tumor antigens for immunotherapy of breast cancer. Breast Dis 20:73–79PubMed

17.

Campbell BJ, Yu LG, Rhodes JM (2001) Altered glycosylation in inflammatory bowel disease: a possible role in cancer development. Glycoconj J 18(11–12):851–858CrossRefPubMed

18.

Jerome KR, Kirk AD, Pecher G, Ferguson WW, Finn OJ (1997) A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis. Cancer Immunol Immunother 43(6):355–360CrossRefPubMed

19.

Nakajima M, Manabe T, Niki Y, Matsushima T (1998) Serum KL-6 level as a monitoring marker in a patient with pulmonary alveolar proteinosis. Thorax 53(9):809–811CrossRefPubMed

20.

Takaishi H, Ohara S, Hotta K et al (2000) Circulating autoantibodies against purified colonic mucin in ulcerative colitis. J Gastroenterol 35(1):20–27CrossRefPubMed

21.

Kohno N (1999) Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest 46:151–158PubMed

22.

Vlad AM, Muller S, Cudic M et al (2002) Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 196(11):1435–1446CrossRefPubMed

23.

Okamura K, Kiyoshima T, Shima K et al (2002) Immunohistochemical expression of CA19-9 and CA125 in mucoepidermoid and adenoid cystic carcinomas of the salivary gland. Oral Oncol 38(3):244–250CrossRefPubMed

24.

Mink PJ, Sherman ME, Devesa SS (2002) Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978–1998. Cancer 95(11):2380–2389CrossRefPubMed

25.

Tipples G, Beirnes J, Hiebert J et al (2008) Laboratory guidelines for the diagnosis of mumps v.3 (3 April 2008), http://www.nml-lnm.gc.ca/guide/docs/Mumps_Lab_guide.pdf. Accessed 14 July 2009

26.

Jin L, Beard S, Brown DW (1999) Genetic heterogeneity of mumps virus in the United Kingdom: identification of two new genotypes. J Infect Dis 180(3):829–833CrossRefPubMed

Title: Mumps and ovarian cancer: modern interpretation of an historic association
Authors: Daniel W. Cramer
Allison F. Vitonis
Simone P. Pinheiro
John R. McKolanis
Raina N. Fichorova
Kevin E. Brown
Todd F. Hatchette
Olivera J. Finn
Publication date: 01-08-2010
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 8/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-010-9546-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2010

Alcohol intake and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium (PanScan)

Interleukin-22 genetic polymorphisms and risk of colon cancer

Diabetes and risk of incident colorectal cancer in a prospective cohort of women

Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men

Antioxidant and DNA methylation-related nutrients and risk of distal colorectal cancer

Age-period-cohort analysis of cancers not related to tobacco, screening, or HIV: sex and race differences

Keynote webinar | Spotlight on antibody–drug conjugates in cancer